Arcturus' COVID-19 vaccine ARCT-154 enters Phase III trial in Japan; CSL collaboration effective

Arcturus Therapeutics Holdings Inc.

Meiji Seika Pharma initiated a Phase III trial of ARCT-154 (self-amplifying mRNA COVID-19 vaccine) in Japan with 780 participants; half receive ARCT-154 as a booster.
The trial will evaluate non-inferiority of ARCT-154 as a booster series compared to a comparator group.
CSL Seqirus announced that the previously disclosed collaboration agreement (Nov 1, 2022) with Arcturus became effective on December 8, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.